<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472497</url>
  </required_header>
  <id_info>
    <org_study_id>PIO and HTN</org_study_id>
    <nct_id>NCT01472497</nct_id>
  </id_info>
  <brief_title>Effects of Pioglitazone in Hypertensive Patients</brief_title>
  <official_title>Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tottori University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tottori University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance is often complicated with hypertension. AGE and inflammation play
      important roles in insulin resistance. Some studies reported that pioglitazone, insulin
      sensitizer, is effective for patients with insulin resistance, however, the mechanisms are
      still unclear. The aim of this study to evaluate the effect of pioglitazone compared with
      glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive
      patients during oral glucose tolerance test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>advanced glycation end-product (AGE)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac function (echo and BNP)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>glymepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>pioglitazone (15mg) once a day for 24 weeks</description>
    <arm_group_label>glymepiride</arm_group_label>
    <other_name>actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension with insulin resistance

        Exclusion Criteria:

          -  Chronic systolic heart failure, ACS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuhide Ogino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tottori University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>June 3, 2012</last_update_submitted>
  <last_update_submitted_qc>June 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tottori University Hospital</investigator_affiliation>
    <investigator_full_name>Kazuhide Ogino</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>oral glucose tolerance test</keyword>
  <keyword>AGE</keyword>
  <keyword>inflammatory cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

